View:

Download DOC

Download PDF

Download XLS

Table of Contents

Table of Contents

                                                                    Exhibit 99.1

Contact:
McDavid Stilwel
GTx, Inc.
Manager, Corporate Communications & Financial Analysis
901-523-9700


         GTX INC. ATTAINS PATIENT ENROLLMENT OF ITS PHASE III ADT TRIAL

MEMPHIS, TENN. - Oct. 19, 2005 - GTx, Inc. (Nasdaq: GTXI), the Men's Health
Biotech Company, today announced it has attained its enrollment goal in its
pivotal Phase III clinical trial for the use of ACAPODENE (toremifene citrate)
80 mg for the treatment of the serious side effects of androgen deprivation
therapy (ADT) for men with advanced prostate cancer.

"More than 1,300 patients in the United States and Mexico are now participating
in our Phase III ADT trial. We are on track to have final data from this trial
in the second half of 2007," said Mitchell Steiner, MD, CEO of GTx. "Men on ADT
are at high risk for developing osteoporosis and life threatening fractures.
Studies have shown that average survival is reduced by 39 months in ADT patients
who do develop fractures."

Patients in the randomized, double blind, pivotal Phase III ADT study receive
daily for two years either an 80 mg tablet of toremifene citrate or placebo. The
primary endpoint of the trial is the occurrence of lumbar vertebral fractures.
Secondary endpoints include hot flashes, gynecomastia, improvement in lipid
profiles, and bone mineral density. GTx is conducting this two year study in
accordance with a Special Protocol Assessment (SPA) from the United States Food
and Drug Administration.

Later in this quarter, GTx plans to conduct an interim analysis of bone mineral
density in the first 200 patients to have completed a full year of treatment in
this Phase III trial.

GTx is conducting under a separate SPA another pivotal Phase III trial of
ACAPODENE in a 20 mg dose for the prevention of prostate cancer in high risk men
who have high grade prostatic intraepithelial neoplasia, or high grade PIN.
Under the PIN trial SPA, the timing for the interim efficacy analysis is driven
by the rate of prostate cancer events among study patients. GTx expects the
interim efficacy analysis will occur within 24 months after completing
enrollment of the approximately 1,260 study subjects for the trial. If the
interim efficacy analysis reveals a statistically significant reduction in
prostate cancer, GTx expects to be able to file the New Drug Application (NDA).
GTx will continue to collect efficacy and safety data during the NDA review
process. Patient enrollment for the PIN trial began in the first quarter 2005
and is on track to be completed by the first quarter 2006.

ABOUT GTX

GTx is a biopharmaceutical company dedicated to the discovery, development and
commercialization of therapeutics for cancer and serious conditions related to
men's health. GTx's lead drug discovery and development programs are focused on
small molecules that selectively modulate the effects of estrogens and
androgens, two essential classes of hormones. GTx, headquartered in Memphis,
Tenn., currently has four clinical programs. GTx is





developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor
modulator, or SERM, in two separate clinical programs in men: (1) a pivotal
Phase III clinical trial for the treatment of serious side effects of androgen
deprivation therapy and (2) a pivotal Phase III clinical trial for the
prevention of prostate cancer in high risk men with high grade PIN. In its third
clinical program, GTx is developing ostarine, a selective androgen receptor
modulator, or SARM, for the treatment of muscle wasting associated with acute
conditions such as burns and is evaluating the drug's development to treat
muscle wasting associated with andropause. GTx plans to initiate its first Phase
II clinical trial of ostarine for burn patients in the fourth quarter of 2005.
In its fourth clinical program, GTx and its collaborator, Ortho Biotech
Products, L.P., a subsidiary of Johnson & Johnson, are developing andarine,
another one of GTx's SARMs, for the treatment of cancer cachexia. GTx is working
with Ortho Biotech to plan a Phase II clinical trial of andarine.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements, including, without
limitation, statements related to GTx's clinical trials and its other research
and development programs. These forward-looking statements are based upon GTx's
current expectations. Forward-looking statements involve risks and
uncertainties. GTx's actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a result
of these risks and uncertainties, which include, without limitation, risks that
GTx will not be able to commercialize its product candidates if clinical trials
do not demonstrate safety and efficacy in humans; and if the Company is not able
to obtain required regulatory approvals, the Company will not be able to
commercialize its product candidates. You should not place undue reliance on
these forward-looking statements, which apply only as of the date of this press
release. GTx's prospectus supplement filed with the U.S. Securities & Exchange
Commission. (the"SEC") pursuant to Rule 424(b)(5) on October 12, 2005, contains
under the heading "Risk Factors" a more comprehensive description of these and
other risks to which GTx is subject. GTx expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in its expectations with
regard thereto or any change in events, conditions or circumstances on which any
such statements are based.